{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T10:22:51Z","timestamp":1707733371790},"reference-count":110,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"DOI":"10.7759\/cureus.48798","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T17:25:11Z","timestamp":1699982711000},"source":"Crossref","is-referenced-by-count":1,"title":["Mechanisms and Treatment Options for Hyperthyroid-Induced Osteoporosis: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Robert  M","family":"Branstetter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahib  K","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collin  A","family":"Toups","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda  N","family":"Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross DS","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, et al.. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016, 26:1343-421. 10.1089\/thy.2016.0229","journal-title":"Thyroid"},{"key":"ref2","article-title":"Thyrotoxicosis","author":"Blick C","year":"2023","unstructured":"Blick C, Nguyen M, Jialal I. Thyrotoxicosis. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref3","article-title":"Hyperthyroidism","author":"Mathew P","year":"2023","unstructured":"Mathew P, Kaur J, Rawla P. Hyperthyroidism. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref4","article-title":"Subclinical hyperthyroidism: when to consider treatment","volume":"95","author":"Donangelo I","year":"2017","unstructured":"Donangelo I, Suh SY. Subclinical hyperthyroidism: when to consider treatment. Am Fam Physician. 2017, 95:710-6.","journal-title":"Am Fam Physician"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.3447","article-title":"Management of subclinical hyperthyroidism","volume":"10","author":"Santos Palacios S","year":"2012","unstructured":"Santos Palacios S, Pascual-Corrales E, Galofre JC. Management of subclinical hyperthyroidism. Int J Endocrinol Metab. 2012, 10:490-6. 10.5812\/ijem.3447","journal-title":"Int J Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2019.11.01","article-title":"Hyperthyroidism","volume":"9","author":"Doubleday AR","year":"2020","unstructured":"Doubleday AR, Sippel RS. Hyperthyroidism. Gland Surg. 2020, 9:124-35. 10.21037\/gs.2019.11.01","journal-title":"Gland Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00278-6","article-title":"Hyperthyroidism","volume":"388","author":"De Leo S","year":"2016","unstructured":"De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016, 388:906-18. 10.1016\/S0140-6736(16)00278-6","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2013.38685","article-title":"Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology","volume":"9","author":"Ertek S","year":"2013","unstructured":"Ertek S, Cicero AF. Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology. Arch Med Sci. 2013, 9:944-52. 10.5114\/aoms.2013.38685","journal-title":"Arch Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041034","article-title":"Thyroid hormone diseases and osteoporosis","volume":"9","author":"Delitala AP","year":"2020","unstructured":"Delitala AP, Scuteri A, Doria C. Thyroid hormone diseases and osteoporosis. J Clin Med. 2020, 9:1034. 10.3390\/jcm9041034","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-09-20-5653","article-title":"Thyroid disease: long-term management of hyperthyroidism and hypothyroidism","volume":"50","author":"Hughes K","year":"2021","unstructured":"Hughes K, Eastman C. Thyroid disease: long-term management of hyperthyroidism and hypothyroidism. Aust J Gen Pract. 2021, 50:36-42. 10.31128\/AJGP-09-20-5653","journal-title":"Aust J Gen Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-200003000-00016","article-title":"Osteoporosis","author":"Lane JM","year":"2000","unstructured":"Lane JM, Russell L, Khan SN. Osteoporosis. Clin Orthop Relat Res. 2000, 139-50. 10.1097\/00003086-200003000-00016","journal-title":"Clin Orthop Relat Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.14-2-187","article-title":"Osteoporosis and fracture risk in older people","volume":"14","author":"Coughlan T","year":"2014","unstructured":"Coughlan T, Dockery F. Osteoporosis and fracture risk in older people. Clin Med (Lond). 2014, 14:187-91. 10.7861\/clinmedicine.14-2-187","journal-title":"Clin Med (Lond)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0000000000000572","article-title":"Bone health and osteoporosis prevention and treatment","volume":"63","author":"Mu\u00f1oz M","year":"2020","unstructured":"Mu\u00f1oz M, Robinson K, Shibli-Rahhal A. Bone health and osteoporosis prevention and treatment. Clin Obstet Gynecol. 2020, 63:770-87. 10.1097\/GRF.0000000000000572","journal-title":"Clin Obstet Gynecol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0118","article-title":"Secondary osteoporosis: pathophysiology and management","volume":"173","author":"Mirza F","year":"2015","unstructured":"Mirza F, Canalis E. Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015, 173:R131-51. 10.1530\/EJE-15-0118","journal-title":"Eur J Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10030149","article-title":"The influence of thyroid pathology on osteoporosis and fracture risk: a review","volume":"10","author":"Apostu D","year":"2020","unstructured":"Apostu D, Lucaciu O, Oltean-Dan D, Mure\u0219an AD, Moisescu-Pop C, Maxim A, Benea H. The influence of thyroid pathology on osteoporosis and fracture risk: a review. Diagnostics (Basel). 2020, 10:149. 10.3390\/diagnostics10030149","journal-title":"Diagnostics (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/638727","article-title":"Metabolic and clinical consequences of hyperthyroidism on bone density","volume":"2013","author":"Gorka J","year":"2013","unstructured":"Gorka J, Taylor-Gjevre RM, Arnason T. Metabolic and clinical consequences of hyperthyroidism on bone density. Int J Endocrinol. 2013, 2013:638727. 10.1155\/2013\/638727","journal-title":"Int J Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1365.035","article-title":"Bone remodeling","volume":"1092","author":"Hadjidakis DJ","year":"2006","unstructured":"Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006, 1092:385-96. 10.1196\/annals.1365.035","journal-title":"Ann N Y Acad Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s1043-2760(03)00144-9","article-title":"The molecular actions of thyroid hormone in bone","volume":"14","author":"Bassett JH","year":"2003","unstructured":"Bassett JH, Williams GR. The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab. 2003, 14:356-64. 10.1016\/s1043-2760(03)00144-9","journal-title":"Trends Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group","volume":"332","author":"Cummings SR","year":"1995","unstructured":"Cummings SR, Nevitt MC, Browner WS, et al.. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995, 332:767-73. 10.1056\/NEJM199503233321202","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-7-200104030-00009","article-title":"Risk for fracture in women with low serum levels of thyroid-stimulating hormone","volume":"134","author":"Bauer DC","year":"2001","unstructured":"Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001, 134:561-8. 10.7326\/0003-4819-134-7-200104030-00009","journal-title":"Ann Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1089\/105072503322238854","article-title":"Hyperthyroidism, bone mineral, and fracture risk--a meta-analysis","volume":"13","author":"Vestergaard P","year":"2003","unstructured":"Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk--a meta-analysis. Thyroid. 2003, 13:585-93. 10.1089\/105072503322238854","journal-title":"Thyroid"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.22540\/JRPMS-03-060","article-title":"Impact of subclinical hyperthyroidism on bone","volume":"3","author":"Koutroumpi S","year":"2019","unstructured":"Koutroumpi S, Stratigou T, Vlassopoulou V. Impact of subclinical hyperthyroidism on bone. JRPMS. 2019, 3:60-6. 10.22540\/JRPMS-03-060","journal-title":"JRPMS"},{"key":"ref23","article-title":"Graves disease","author":"Pokhrel B","year":"2023","unstructured":"Pokhrel B, Bhusal K. Graves disease. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/2042018811408488","article-title":"Current concepts in Graves' disease","volume":"2","author":"Girgis CM","year":"2011","unstructured":"Girgis CM, Champion BL, Wall JR. Current concepts in Graves' disease. Ther Adv Endocrinol Metab. 2011, 2:135-44. 10.1177\/2042018811408488","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1306-5","article-title":"Epidemiology, management and outcomes of Graves' disease-real life data","volume":"56","author":"Hussain YS","year":"2017","unstructured":"Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of Graves' disease-real life data. Endocrine. 2017, 56:568-78. 10.1007\/s12020-017-1306-5","journal-title":"Endocrine"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1402","article-title":"Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype","volume":"91","author":"Manji N","year":"2006","unstructured":"Manji N, Carr-Smith JD, Boelaert K, et al.. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab. 2006, 91:4873-80. 10.1210\/jc.2006-1402","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.12701\/jyms.2022.00444","article-title":"Long-term management of Graves disease: a narrative review","volume":"40","author":"Kim HJ","year":"2023","unstructured":"Kim HJ. Long-term management of Graves disease: a narrative review. J Yeungnam Med Sci. 2023, 40:12-22. 10.12701\/jyms.2022.00444","journal-title":"J Yeungnam Med Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves' disease","volume":"6","author":"Davies TF","year":"2020","unstructured":"Davies TF, Andersen S, Latif R, et al.. Graves' disease. Nat Rev Dis Primers. 2020, 6:52. 10.1038\/s41572-020-0184-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1055\/a-0723-9023","article-title":"Thyrotropin receptor blocking antibodies","volume":"50","author":"Diana T","year":"2018","unstructured":"Diana T, Olivo PD, Kahaly GJ. Thyrotropin receptor blocking antibodies. Horm Metab Res. 2018, 50:853-62. 10.1055\/a-0723-9023","journal-title":"Horm Metab Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn RS","year":"2010","unstructured":"Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010, 362:726-38. 10.1056\/NEJMra0905750","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506050-00003","article-title":"Pretibial myxedema: pathophysiology and treatment options","volume":"6","author":"Fatourechi V","year":"2005","unstructured":"Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol. 2005, 6:295-309. 10.2165\/00128071-200506050-00003","journal-title":"Am J Clin Dermatol"},{"key":"ref32","article-title":"Multinodular goiter","author":"Medeiros-Neto G","year":"2016","unstructured":"Medeiros-Neto G. Multinodular goiter. Endotext [Internet]. Feingold KR, Anawalt B, Blackman MR, et al. (ed):  MDText.com, Inc., South Dartmouth, MA; 2016."},{"key":"ref33","article-title":"Plummer disease","author":"Khalid N","year":"2023","unstructured":"Khalid N, Can AS. Plummer disease. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref34","article-title":"Diffuse toxic goiter","author":"Singh G","year":"2023","unstructured":"Singh G, Anastasopoulou C, Correa R. Diffuse toxic goiter. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref35","article-title":"Goiter","author":"Can AS","year":"2023","unstructured":"Can AS, Rehman A. Goiter. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.14744\/SEMB.2022.56514","article-title":"Non-toxic multinodular goiter: from etiopathogenesis to treatment","volume":"56","author":"Unlu MT","year":"2022","unstructured":"Unlu MT, Kostek M, Aygun N, Isgor A, Uludag M. Non-toxic multinodular goiter: from etiopathogenesis to treatment. Sisli Etfal Hastan Tip Bul. 2022, 56:21-40. 10.14744\/SEMB.2022.56514","journal-title":"Sisli Etfal Hastan Tip Bul"},{"key":"ref37","article-title":"Nontoxic goiter","author":"Alkabban FM","year":"2023","unstructured":"Alkabban FM, Patel BC. Nontoxic goiter. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/BF02893034","article-title":"Autoimmune thyroid disorders-an update","volume":"20","author":"Swain M","year":"2005","unstructured":"Swain M, Swain T, Mohanty BK. Autoimmune thyroid disorders-an update. Indian J Clin Biochem. 2005, 20:9-17. 10.1007\/BF02893034","journal-title":"Indian J Clin Biochem"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1159\/000515126","article-title":"Prevention of iodinated contrast media-induced hyperthyroidism in patients with euthyroid goiter","volume":"10","author":"Pelewicz K","year":"2021","unstructured":"Pelewicz K, Wolny R, Bednarczuk T, Mi\u015bkiewicz P. Prevention of iodinated contrast media-induced hyperthyroidism in patients with euthyroid goiter. Eur Thyroid J. 2021, 10:306-13. 10.1159\/000515126","journal-title":"Eur Thyroid J"},{"key":"ref40","article-title":"Jod-basedow syndrome","author":"Rose HR","year":"2023","unstructured":"Rose HR, Zulfiqar H, Anastasopoulou C. Jod-basedow syndrome. StatPearls [Internet]. StatPearls Publishing, Treasure, FL; 2023."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S0030-6665(02)00157-3","article-title":"Multinodular goiter","volume":"36","author":"Day TA","year":"2003","unstructured":"Day TA, Chu A, Hoang KG. Multinodular goiter. Otolaryngol Clin North Am. 2003, 36:35-54. 10.1016\/S0030-6665(02)00157-3","journal-title":"Otolaryngol Clin North Am"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.4158\/EP161208.GL","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazone Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules--2016 update","volume":"22","author":"Gharib H","year":"2016","unstructured":"Gharib H, Papini E, Garber JR, et al.. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazone Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules--2016 update. Endocr Pract. 2016, 22:622-39. 10.4158\/EP161208.GL","journal-title":"Endocr Pract"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-008-9566-0","article-title":"Evidence-based management of toxic multinodular goiter (Plummer's disease)","volume":"32","author":"Porterfield JR Jr","year":"2008","unstructured":"Porterfield JR Jr, Thompson GB, Farley DR, Grant CS, Richards ML. Evidence-based management of toxic multinodular goiter (Plummer's disease). World J Surg. 2008, 32:1278-84. 10.1007\/s00268-008-9566-0","journal-title":"World J Surg"},{"key":"ref44","article-title":"Diagnostic imaging work up in multi-nodular goiter","volume":"35","author":"Luster M","year":"2010","unstructured":"Luster M, Verburg FA, Scheidhauer K. Diagnostic imaging work up in multi-nodular goiter. Minerva Endocrinol. 2010, 35:153-9.","journal-title":"Minerva Endocrinol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2015.12.041","article-title":"Bilateral benign multinodular goiter: what is the adequate surgical therapy? A review of literature","volume":"28","author":"Mauriello C","year":"2016","unstructured":"Mauriello C, Marte G, Canfora A, et al.. Bilateral benign multinodular goiter: what is the adequate surgical therapy? A review of literature. Int J Surg. 2016, 28:S7-12. 10.1016\/j.ijsu.2015.12.041","journal-title":"Int J Surg"},{"key":"ref46","article-title":"Thyroid adenoma","author":"Mulita F","year":"2023","unstructured":"Mulita F, Anjum F. Thyroid adenoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0776","article-title":"Decision-analytic modeling studies in prevention and treatment of iodine deficiency and thyroid disorders: a systematic overview","volume":"30","author":"Rochau U","year":"2020","unstructured":"Rochau U, Qerimi Rushaj V, Schaffner M, et al.. Decision-analytic modeling studies in prevention and treatment of iodine deficiency and thyroid disorders: a systematic overview. Thyroid. 2020, 30:746-58. 10.1089\/thy.2018.0776","journal-title":"Thyroid"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6717","article-title":"Gene expression differences between thyroid carcinoma, thyroid adenoma and normal thyroid tissue","volume":"40","author":"Wang Q","year":"2018","unstructured":"Wang Q, Shen Y, Ye B, et al.. Gene expression differences between thyroid carcinoma, thyroid adenoma and normal thyroid tissue. Oncol Rep. 2018, 40:3359-69. 10.3892\/or.2018.6717","journal-title":"Oncol Rep"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2001-012054","article-title":"Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth","volume":"87","author":"Martelli ML","year":"2002","unstructured":"Martelli ML, Iuliano R, Le Pera I, et al.. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab. 2002, 87:4728-35. 10.1210\/jc.2001-012054","journal-title":"J Clin Endocrinol Metab"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0302","article-title":"A somatic gain-of-function mutation in the thyrotropin receptor gene producing a toxic adenoma in an infant","volume":"19","author":"Kohn B","year":"2009","unstructured":"Kohn B, Grasberger H, Lam LL, Ferrara AM, Refetoff S. A somatic gain-of-function mutation in the thyrotropin receptor gene producing a toxic adenoma in an infant. Thyroid. 2009, 19:187-91. 10.1089\/thy.2008.0302","journal-title":"Thyroid"},{"key":"ref51","article-title":"TSH receptor mutations and diseases","author":"Kleinau G","year":"2017","unstructured":"Kleinau G, Vassart G. TSH receptor mutations and diseases. Endotext [Internet]. Feingold KR, Anawalt B, Blackman MR, et al. (ed): MDText.com, Inc., South Dartmouth, MA; 2017."},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.40","article-title":"Analysis of RAS mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population","volume":"1","author":"Jeong SH","year":"2018","unstructured":"Jeong SH, Hong HS, Lee EH, Kwak JJ, Lee JY. Analysis of RAS mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population. Endocrinol Diabetes Metab. 2018, 1:e00040. 10.1002\/edm2.40","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref53","article-title":"Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors","volume":"3","author":"Challeton C","year":"1995","unstructured":"Challeton C, Bounacer A, Du Villard JA, et al.. Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Oncogene. 1995, 3:601-3.","journal-title":"Oncogene"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0405","article-title":"Follicular adenoma and carcinoma of the thyroid gland","volume":"16","author":"McHenry CR","year":"2011","unstructured":"McHenry CR, Phitayakorn R. Follicular adenoma and carcinoma of the thyroid gland. Oncologist. 2011, 16:585-93. 10.1634\/theoncologist.2010-0405","journal-title":"Oncologist"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S307166","article-title":"The value of sonography in distinguishing follicular thyroid carcinoma from adenoma","volume":"13","author":"Li W","year":"2021","unstructured":"Li W, Song Q, Lan Y, et al.. The value of sonography in distinguishing follicular thyroid carcinoma from adenoma. Cancer Manag Res. 2021, 13:3991-4002. 10.2147\/CMAR.S307166","journal-title":"Cancer Manag Res"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-2197.2006.03667.x","article-title":"Incidental thyroid carcinoma in a large series of consecutive patients operated on for benign thyroid disease","volume":"76","author":"Miccoli P","year":"2006","unstructured":"Miccoli P, Minuto MN, Galleri D, et al.. Incidental thyroid carcinoma in a large series of consecutive patients operated on for benign thyroid disease. ANZ J Surg. 2006, 76:123-6. 10.1111\/j.1445-2197.2006.03667.x","journal-title":"ANZ J Surg"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60047","article-title":"Mechanisms of thyroid hormone action","volume":"122","author":"Brent GA","year":"2012","unstructured":"Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012, 122:3035-43. 10.1172\/JCI60047","journal-title":"J Clin Invest"},{"key":"ref58","article-title":"Physiology, thyroid hormone","author":"Shahid MA","year":"2023","unstructured":"Shahid MA, Ashraf MA, Sharma S. Physiology, thyroid hormone. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref59","article-title":"Thyroid disease and pregnancy","author":"Singh S","year":"2023","unstructured":"Singh S, Sandhu S. Thyroid disease and pregnancy. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref60","article-title":"Physiology, thyroid function","author":"Armstrong M","year":"2023","unstructured":"Armstrong M, Asuka E, Fingeret A. Physiology, thyroid function. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2001.81.3.1097","article-title":"Physiological and molecular basis of thyroid hormone action","volume":"81","author":"Yen PM","year":"2001","unstructured":"Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001, 81:1097-142. 10.1152\/physrev.2001.81.3.1097","journal-title":"Physiol Rev"},{"key":"ref62","article-title":"Effects of thyroid status on bone metabolism: a primary role for thyroid stimulating hormone or thyroid hormone","volume":"30","author":"Galliford TM","year":"2005","unstructured":"Galliford TM, Murphy E, Williams AJ, et al.. Effects of thyroid status on bone metabolism: a primary role for thyroid stimulating hormone or thyroid hormone. Minerva Endocrinol. 2005, 30:237-46.","journal-title":"Minerva Endocrinol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-014-0012-0","article-title":"The influence of thyroid dysfunction on bone metabolism","volume":"7","author":"Tuchendler D","year":"2014","unstructured":"Tuchendler D, Bolanowski M. The influence of thyroid dysfunction on bone metabolism. Thyroid Res. 2014, 7:12. 10.1186\/s13044-014-0012-0","journal-title":"Thyroid Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070302","article-title":"Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats","volume":"22","author":"Sampath TK","year":"2007","unstructured":"Sampath TK, Simic P, Sendak R, et al.. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res. 2007, 22:849-59. 10.1359\/jbmr.070302","journal-title":"J Bone Miner Res"},{"key":"ref65","article-title":"Actions of thyroid hormones in bone","volume":"60","author":"Williams GR","year":"2009","unstructured":"Williams GR. Actions of thyroid hormones in bone. Endokrynol Pol. 2009, 60:380-8.","journal-title":"Endokrynol Pol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1530\/joe-12-0059","article-title":"The skeletal consequences of thyrotoxicosis","volume":"213","author":"Nicholls JJ","year":"2012","unstructured":"Nicholls JJ, Brassill MJ, Williams GR, et al.. The skeletal consequences of thyrotoxicosis. J Endocrinol. 2012, 213:209-21. 10.1530\/joe-12-0059","journal-title":"J Endocrinol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R109.041087","article-title":"Cellular and molecular mechanisms of bone remodeling","volume":"285","author":"Raggatt LJ","year":"2010","unstructured":"Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010, 285:25103-8. 10.1074\/jbc.R109.041087","journal-title":"J Biol Chem"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1210\/er.2015-1106","article-title":"Role of thyroid hormones in skeletal development and bone maintenance","volume":"37","author":"Bassett JH","year":"2016","unstructured":"Bassett JH, Williams GR. Role of thyroid hormones in skeletal development and bone maintenance. Endocr Rev. 2016, 37:135-87. 10.1210\/er.2015-1106","journal-title":"Endocr Rev"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-13-3-596","article-title":"The thyrotropin receptor and the regulation of thyrocyte function and growth","volume":"13","author":"Vassart G","year":"1992","unstructured":"Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev. 1992, 13:596-611. 10.1210\/edrv-13-3-596","journal-title":"Endocr Rev"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-021-00715-8","article-title":"Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation","volume":"21","author":"Deng T","year":"2021","unstructured":"Deng T, Zhang W, Zhang Y, et al.. Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation. BMC Endocr Disord. 2021, 21:49. 10.1186\/s12902-021-00715-8","journal-title":"BMC Endocr Disord"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.2.228","article-title":"Subclinical thyroid disease: scientific review and guidelines for diagnosis and management","volume":"291","author":"Surks MI","year":"2004","unstructured":"Surks MI, Ortiz E, Daniels GH, et al.. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004, 291:228-38. 10.1001\/jama.291.2.228","journal-title":"JAMA"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb02403.x","article-title":"Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?","volume":"39","author":"F\u00f6ldes J","year":"1993","unstructured":"F\u00f6ldes J, Tarj\u00e1n G, Szathmari M, Varga F, Krasznai I, Horvath C. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?. Clin Endocrinol (Oxf). 1993, 39:521-7. 10.1111\/j.1365-2265.1993.tb02403.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0158","article-title":"The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Troms\u00f8 study","volume":"18","author":"Grimnes G","year":"2008","unstructured":"Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jorde R. The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Troms\u00f8 study. Thyroid. 2008, 18:1147-55. 10.1089\/thy.2008.0158","journal-title":"Thyroid"},{"key":"ref74","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1983.00350030052010","article-title":"Exogenous hyperthyroidism with osteoporosis","volume":"143","author":"Fallon MD","year":"1983","unstructured":"Fallon MD, Perry HM 3rd, Bergfeld M, Droke D, Teitelbaum SL, Avioli LV. Exogenous hyperthyroidism with osteoporosis. Arch Intern Med. 1983, 143:442-4.","journal-title":"Arch Intern Med"},{"key":"ref75","article-title":"Osseous effects of hyperthyroidism [Article in French]","volume":"39","author":"Bianchi GS","year":"1972","unstructured":"Bianchi GS, Meunier P, Courpron P, Edouard C, Bernard J, Vignon G. Osseous effects of hyperthyroidism [Article in French]. Rev Rhum Mal Osteoartic. 1972, 39:19-32.","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-9-199905040-00016","article-title":"The effect of thyroid hormone on skeletal integrity","volume":"130","author":"Greenspan SL","year":"1999","unstructured":"Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med. 1999, 130:750-8. 10.7326\/0003-4819-130-9-199905040-00016","journal-title":"Ann Intern Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0139","article-title":"Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study","volume":"161","author":"Svare A","year":"2009","unstructured":"Svare A, Nilsen TI, Bj\u00f8ro T, Forsmo S, Schei B, Langhammer A. Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study. Eur J Endocrinol. 2009, 161:779-86. 10.1530\/EJE-09-0139","journal-title":"Eur J Endocrinol"},{"key":"ref78","doi-asserted-by":"crossref","DOI":"10.1016\/S0889-8529(18)30338-4","article-title":"Effects of thyroid hormones on bone and mineral metabolism","volume":"19","author":"Mosekilde L","year":"1990","unstructured":"Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am. 1990, 19:35-63.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(67)91766-7","article-title":"Plasma levels of ionised calcium and magnesium in thyroid disease","volume":"24","author":"Frizel D","year":"1967","unstructured":"Frizel D, Malleson A, Marks V. Plasma levels of ionised calcium and magnesium in thyroid disease. Lancet. 1967, 24:1360-1. 10.1016\/s0140-6736(67)91766-7","journal-title":"Lancet"},{"key":"ref80","article-title":"Physiology, parathyroid hormone","author":"Khan M","year":"2023","unstructured":"Khan M, Jose A, Sharma S. Physiology, parathyroid hormone. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5161","article-title":"Subclinical thyroid dysfunction and fracture risk: a meta-analysis","volume":"313","author":"Blum MR","year":"2015","unstructured":"Blum MR, Bauer DC, Collet TH, et al.. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015, 313:2055-65. 10.1001\/jama.2015.5161","journal-title":"JAMA"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-11-15","article-title":"Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men","volume":"11","author":"El Hadidy el HM","year":"2011","unstructured":"El Hadidy el HM, Ghonaim M, El Gawad SSh, El Atta MA. Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men. BMC Endocr Disord. 2011, 11:15. 10.1186\/1472-6823-11-15","journal-title":"BMC Endocr Disord"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.40823","article-title":"Association between subclinical thyroid dysfunction and fracture risk","volume":"5","author":"Daya NR","year":"2022","unstructured":"Daya NR, Fretz A, Martin SS, Lutsey PL, Echouffo-Tcheugui JB, Selvin E, Juraschek SP. Association between subclinical thyroid dysfunction and fracture risk. JAMA Netw Open. 2022, 5:e2240823. 10.1001\/jamanetworkopen.2022.40823","journal-title":"JAMA Netw Open"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1774","article-title":"A prospective study of thyroid function, bone loss, and fractures in older men: the MrOS study","volume":"28","author":"Waring AC","year":"2013","unstructured":"Waring AC, Harrison S, Fink HA, et al.. A prospective study of thyroid function, bone loss, and fractures in older men: the MrOS study. J Bone Miner Res. 2013, 28:472-9. 10.1002\/jbmr.1774","journal-title":"J Bone Miner Res"},{"key":"ref85","article-title":"Propylthiouracil","author":"Amisha F","year":"2023","unstructured":"Amisha F, Rehman A. Propylthiouracil. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref86","article-title":"Methimazole","author":"Singh G","year":"2023","unstructured":"Singh G, Correa R. Methimazole. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0141","article-title":"Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline","volume":"92","author":"Abalovich M","year":"2007","unstructured":"Abalovich M, Amino N, Barbour LA, et al.. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007, 92:S1-47. 10.1210\/jc.2007-0141","journal-title":"J Clin Endocrinol Metab"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.65.6.755","article-title":"Propylthiouracil-induced agranulocytosis as a rare complication of antithyroid drugs in a patient with Graves' disease","volume":"65","author":"Rabelo PN","year":"2019","unstructured":"Rabelo PN, Rabelo PN, Paula AF, et al.. Propylthiouracil-induced agranulocytosis as a rare complication of antithyroid drugs in a patient with Graves' disease. Rev Assoc Med Bras (1992). 2019, 65:755-60. 10.1590\/1806-9282.65.6.755","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1100\/2012\/548796","article-title":"Thyroid function after subtotal thyroidectomy in patients with Graves' hyperthyroidism","volume":"2012","author":"Limonard EJ","year":"2012","unstructured":"Limonard EJ, Bisschop PH, Fliers E, Nieveen van Dijkum EJ. Thyroid function after subtotal thyroidectomy in patients with Graves' hyperthyroidism. ScientificWorldJournal. 2012, 2012:548796. 10.1100\/2012\/548796","journal-title":"ScientificWorldJournal"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-12-0059","article-title":"The skeletal consequences of thyrotoxicosis","volume":"213","author":"Nicholls JJ","year":"2012","unstructured":"Nicholls JJ, Brassill MJ, Williams GR, Bassett JH. The skeletal consequences of thyrotoxicosis. J Endocrinol. 2012, 213:209-21. 10.1530\/JOE-12-0059","journal-title":"J Endocrinol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008, 83:1032-45. 10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell RG","year":"2007","unstructured":"Russell RG, Xia Z, Dunford JE, et al.. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007, 1117:209-57. 10.1196\/annals.1402.089","journal-title":"Ann N Y Acad Sci"},{"key":"ref93","article-title":"Bisphosphonate","author":"Ganesan K","year":"2023","unstructured":"Ganesan K, Goyal A, Roane D. Bisphosphonate. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2020.05.004","article-title":"How to manage osteoporosis before the age of 50","volume":"138","author":"Rozenberg S","year":"2020","unstructured":"Rozenberg S, Bruy\u00e8re O, Bergmann P, et al.. How to manage osteoporosis before the age of 50. Maturitas. 2020, 138:14-25. 10.1016\/j.maturitas.2020.05.004","journal-title":"Maturitas"},{"key":"ref95","article-title":"Calcitonin","author":"McLaughlin MB","year":"2023","unstructured":"McLaughlin MB, Jialal I. Calcitonin. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref96","article-title":"Bazedoxifene","author":"Raina PM","year":"2023","unstructured":"Raina PM, Parmar M. Bazedoxifene. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref97","article-title":"Raloxifene","author":"Quintanilla Rodriguez BS","year":"2023","unstructured":"Quintanilla Rodriguez BS, Correa R. Raloxifene. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler DL","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther. 2022, 39:58-74. 10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e318267f909","article-title":"Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture","volume":"20","author":"Simon JA","year":"2013","unstructured":"Simon JA, Recknor C, Moffett AH Jr, et al.. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause. 2013, 20:130-7. 10.1097\/gme.0b013e318267f909","journal-title":"Menopause"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3654","article-title":"Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension I trials","volume":"34","author":"Kim TY","year":"2019","unstructured":"Kim TY, Bauer DC, McNabb BL, Schafer AL, Cosman F, Black DM, Eastell R. Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension I trials. J Bone Miner Res. 2019, 34:810-6. 10.1002\/jbmr.3654","journal-title":"J Bone Miner Res"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier B","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int. 2016, 27:1923-5. 10.1007\/s00198-015-3380-y","journal-title":"Osteoporos Int"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial","volume":"99","author":"Leder BZ","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV, et al.. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial. J Clin Endocrinol Metab. 2014, 99:1694-700. 10.1210\/jc.2013-4440","journal-title":"J Clin Endocrinol Metab"},{"key":"ref103","article-title":"Teriparatide","author":"Vall H","year":"2023","unstructured":"Vall H, Parmar M. Teriparatide. Statpearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman AB","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, et al.. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005, 26:688-703. 10.1210\/er.2004-0006","journal-title":"Endocr Rev"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.3390\/dj4040041","article-title":"Role of teriparatide in medication-related osteonecrosis of the jaws (MRONJ)","volume":"4","author":"Kwon YD","year":"2016","unstructured":"Kwon YD, Kim DY. Role of teriparatide in medication-related osteonecrosis of the jaws (MRONJ). Dent J (Basel). 2016, 4:41. 10.3390\/dj4040041","journal-title":"Dent J (Basel)"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S31067","article-title":"Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis","volume":"7","author":"Dore RK","year":"2013","unstructured":"Dore RK. Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis. Patient Prefer Adherence. 2013, 7:435-46. 10.2147\/PPA.S31067","journal-title":"Patient Prefer Adherence"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2023.01.003","article-title":"Pharmacologic and nonpharmacologic treatment modalities for bone loss in spinal cord injury - proposal for combined approach","volume":"26","author":"Dharnipragada R","year":"2023","unstructured":"Dharnipragada R, Ahiarakwe U, Gupta R, et al.. Pharmacologic and nonpharmacologic treatment modalities for bone loss in spinal cord injury - proposal for combined approach. J Clin Densitom. 2023, 26:101359. 10.1016\/j.jocd.2023.01.003","journal-title":"J Clin Densitom"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000333.pub2","article-title":"Exercise for preventing and treating osteoporosis in postmenopausal women","author":"Howe TE","year":"2011","unstructured":"Howe TE, Shea B, Dawson LJ, et al.. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011, CD000333. 10.1002\/14651858.CD000333.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4840531","article-title":"The effectiveness of physical exercise on bone density in osteoporotic patients","volume":"2018","author":"Benedetti MG","year":"2018","unstructured":"Benedetti MG, Furlini G, Zati A, Letizia Mauro G. The effectiveness of physical exercise on bone density in osteoporotic patients. Biomed Res Int. 2018, 2018:4840531. 10.1155\/2018\/4840531","journal-title":"Biomed Res Int"},{"key":"ref110","article-title":"Vitamin D","author":"Chauhan K","year":"2023","unstructured":"Chauhan K, Shahrokhi M, Huecker MR. Vitamin D. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/195388-mechanisms-and-treatment-options-for-hyperthyroid-induced-osteoporosis-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:06Z","timestamp":1707508506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/195388-mechanisms-and-treatment-options-for-hyperthyroid-induced-osteoporosis-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":110,"URL":"https:\/\/doi.org\/10.7759\/cureus.48798","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,14]]}}}